Farrell Michael J.

Farrell Michael J., chief executive officer of ResMed (RMD) and a director at Zimmer Biomet (ZBH), has been a consistent seller of RMD stock over the past year, with no open-market purchases on record. Across 53 total Form 4 filings spanning two companies, his sales total roughly $30.1 million, while acquisitions—almost entirely option exercises and equity grants—amount to about $8.3 million. The pattern is unambiguous: every open-market transaction in the recent window is a sale, and the only "P" (purchase) code never appears in his history. The selling cadence is mechanical and recurring. On the seventh of each month from January through July 2026, Farrell executed paired transactions in RMD: an option exercise (code M) valued at $730,382.94, followed immediately by a sale (code S) of the same magnitude or larger. The sales ranged from $968,064.34 in June to $1.36 million in February, with the most recent sale on July 7, 2026, at $1.09 million. These are not sporadic dispositions but a steady monthly liquidation of vested options, likely to cover tax obligations and convert equity into cash. The absence of any purchase activity suggests Farrell is not adding to his RMD position at current prices. At ZBH, his activity is purely compensatory. He received three grants (code A) with zero dollar value between December 2025 and June 2026, reflecting routine director compensation rather than any market signal. The only notable non-recurring event was a November 2025 RMD grant valued at $8.34 million, paired with a tax-withholding transaction (code F) of $551,644.82. Overall, Farrell’s Form 4 trail shows a CEO monetizing vested equity on a fixed schedule, with no indication of conviction buying or unusual timing that would suggest a directional bet on either company’s stock.